NDAINJECTIONINJECTABLE
Approved
Dec 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Wyamine Sulfate (mephentermine sulfate) is an injectable sympathomimetic amine approved in 1951 for acute hypotensive states. It acts as an adrenergic stimulant to elevate blood pressure through peripheral vasoconstriction and cardiac stimulation. This legacy product represents a legacy injectable intervention in acute care settings.
LOE Approaching
As LOE approaches on this 70+ year-old product, commercial teams are likely focused on lifecycle management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Wyamine Sulfate offers minimal career growth as a legacy injectable with zero linked job postings and approaching loss-of-exclusivity. This role is suited for professionals focused on lifecycle management, hospital relationships, and operational efficiency rather than market expansion or innovation.
Specialty Pharmaceutical SalesMedical Science Liaison
Worked on WYAMINE SULFATE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.